Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease
NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ('Tiziana' or the 'Company'), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its investigational drug, intranasal foralumab, was featured on a prominent News Channel. The segment highlighted the experiences of the first patient dosed in the company's expanded access program for moderate Alzheimer's disease.
In the segment, Joe and his Wife, Karen, shared their journey and shed light on the hope that innovative therapies like Foralumab offer for individuals battling moderate Alzheimer's, a condition that currently has no cure and limited treatment options.
Watch the full interview here: https://youtu.be/vj6GGzbJfOk?si=lMqkFipmll8GF--o.
Dr. Howard Weiner, Co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital, a founding member of Mass General Brigham healthcare system commented 'Foralumab, administered via a novel intranasal delivery method, aims to target immune system dysregulation associated with Alzheimer's disease, potentially slowing disease progression and improving cognitive function. The recent coverage in the News underscores the growing recognition of Foralumab's promise in the field of neurodegenerative diseases.'
Foralumab's mechanism of action involves modulating the immune system to reduce inflammation, which has been linked to neurodegeneration in Alzheimer's. The expanded access program enables patients who do not have access to clinical trials to receive this promising treatment as part of a compassionate use initiative.
Microglial activation is increasingly recognized as a critical component of neurodegenerative diseases, including Alzheimer's, secondary progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Parkinson's disease. In Alzheimer's, this activation contributes to the pathogenesis alongside increased beta-amyloid and tau protein levels. Cognitive dysfunction in AD has been linked to both tau accumulation and microglial activation, highlighting the need for treatments beyond amyloid-targeting therapies.
Nasal foralumab, a fully human anti-CD3 monoclonal antibody, has shown efficacy in dampening microglial activation through the induction of Tregs, which travel to the brain and modulate neuroinflammation. This therapeutic effect has been validated in animal models and observed in subjects with secondary progressive MS. Nasal foralumab also holds promise as a potential adjunctive therapy that addresses a major component of AD pathogenesis not targeted by anti-amyloid therapies.
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program with either an improvement or stability of disease seen within 6 months in all patients. The FDA has recently allowed an additional 20 patients to be enrolled in this EA program. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).
Activated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development, binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been observed in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. The non-active SPMS intranasal foralumab Phase 2 trial (NCT06292923) began screening patients in November of 2023. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2]
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana's innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana's technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled 'Risk Factors' in Tiziana's Annual Report on Form 20-F for the year ended December 31, 2023, and other periodic reports filed with the Securities and Exchange Commission.The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
For further inquiries:
Tiziana Life Sciences LtdPaul Spencer, Business Development, and Investor Relations+44 (0) 207 495 2379email: info@tizianalifesciences.com
A video accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/df5ac382-7310-419e-b2ef-59f1fd831999
____________________[1] https://www.pnas.org/doi/10.1073/pnas.2220272120[2] https://www.pnas.org/doi/10.1073/pnas.2309221120Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Omada goes public in second recent digital health IPO
This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Omada Health went public Friday, marking the second recent digital health IPO after a dry spell for the sector. The digital chronic condition management company opened at $23 per share, a 21% bump over its public offering price of $19 per share. Omada's debut comes on the heels of virtual musculoskeletal company Hinge Health's IPO last month. 'I think it is definitely a promising bellwether for the industry,' John Beadle, co-founder and managing partner of Aegis Ventures, told Healthcare Dive. Omada, which was founded in 2011 and has raised hundreds of millions of dollars in venture capital funding, offers digital management programs for conditions like diabetes, obesity and hypertension. Care teams also work with patients to build treatment plans and equip users with connected devices like blood pressure cuffs or digital scales. The company filed to go public in May. Now, Omada is trading on Nasdaq under the ticker symbol 'OMDA,' having raised $150 million in its IPO. The firm's public offering price of $19 was at the midpoint of the expected range it released Thursday. Omada's IPO comes as the digital health sector has seen few public offerings in recent years. A surge of companies notched public exits in 2021, but the number has declined significantly in recent years. Many digital health companies that went public during the boom — particularly ones that used mergers with special purpose acquisition companies — performed poorly, and may have been better off as strategic M&A targets, Beadle said. However, the industry seemed poised for more companies to make the leap this year, and their performance could push others to follow in their footsteps, experts told Healthcare Dive late last year. Now, two digital health companies have gone public in recent weeks. Hinge debuted on the New York Stock Exchange in May, opening 23% above its public offering price. Still, the sector isn't seeing a flood of digital health companies moving to go public like in 2021, Beadle said. 'I don't think there's that many companies that are ready and have the operational maturity, growth trajectory [and] outcomes that Hinge and Omada do,' he said. 'But I think both companies were exceptionally well prepared to do well when they went public.' Though Hinge had given back most of its early post-IPO gains by the time of Omada's pricing, its performance still provided a 'good tailwind' for the chronic conditions management firm, Edward Best, co-chair of the capital markets practice at Willkie Farr & Gallagher, said via email. Still, larger macroeconomic conditions will also impact whether more digital health companies decide to make the leap to the public markets. Some technology companies decided to delay their IPOs this spring after tariffs announced by President Donald Trump roiled the markets. Stability is key to the IPO market, as investors will likely choose safer investments during periods of volatility, Best said. Companies need to think about their own operations and readiness to go public as well as broader conditions. 'The IPO market has periods when the window is more open than others. A company that is ready and wants or needs to go public when the window is open should certainly take a long hard look within,' he said. 'Waiting too long could mean missing the window.' Recommended Reading Hinge Health goes public in positive signal for digital health IPOs
Yahoo
27 minutes ago
- Yahoo
How to Organize a Health Technology Business with Focus on 10+ Organizational Archetypes
Discover the evolving organizational structures of digital health businesses in the Pharma and MedTech sectors. This report analyzes 11 HealthTech archetypes over 15 years, offering insights on performance across key KPIs, future trends, and strategic recommendations. Featured companies include Bayer, Roche, and more. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "How to Organize a HealthTech Business?" report has been added to offering. This report sheds light on how to organize digital health businesses, especially at large Pharma and MedTech companies. By looking at how other companies have been managing their HealthTech businesses over the last 15 years, 11 different HealthTech organizational archetypes are being detailed out in the report, including their objectives, responsibilities, team sizes, target partner company stages, governance, value propositions for their partners, business impact evaluations across 4 KPIs and real-life examples from companies who had deployed these structures. Performance of the 11 archetypes are then evaluated and compared across the four main KPIs which are based on finding partners, launching solutions, driving usages & cultural change support. Based on the evaluation of the success and impact of these archetypes, the report presents a benchmarking table of HealthTech business organizations today. With a deep-dive into the evolving trends in HealthTech business organizations responding to the changing market conditions across three main market phases, 5 trend points for future and relevant recommendations are provided on what needs to be done to stay competitive and move forward in growing digital health market. Questions the report answers: What are the archetypes to organize HealthTech businesses at Pharma and MedTech companies? What are the different objectives and responsibilities of each organizational archetype? How are the archetypes governed at larger corporates? How does each organizational archetype perform? Which Pharma and MedTech apply which archetype to manage their HealthTech business today? How did the archetypes evolve to adept the market conditions today? What does the market require for organization of HealthTech businesses in 3-5 years? Interested parties can benefit from this report in the following ways: Consultants: gain insights into different organizational structures within the HealthTech industry, and enhance the ability to advise clients on optimal structuring and strategic alignment for digital health initiatives Strategy heads: understand how leading organizations structure their HealthTech initiatives, which can inform strategic planning and decision-making processes Business unit heads: understand how to integrate digital health solutions into the units effectively, determine the most suitable structure for the unit, and align with overall corporate objectives Digital health unit heads: benchmark your organizational structure against others, know what is needed in terms organizational structure to stay competitive in the growing digital health market, and optimize your organizational structure to foster innovation and integration with business units In this report, the following companies are mentioned: Bayer Roche Biogen Sanofi Siemens Healtineers GE Healthcare Janssen (J&J) MSD Merck KGaA Novartis Becton Dickenson and Company *30 min report consultation with a research analyst available with the purchase of an enterprise license Key Topics Covered: Archetype-1: Central Teams Archetype-2: De-Central Teams Archetype-3: Carve-Outs Archetype-4: Innovation Hubs Archetype-5: Incubators Archetype-6: Accelerators Archetype-7: Collaborative Accelerators Archetype-8: People Accelerators Archetype-9: Marketplace Organizations Archetype-10: Venture Funds Archetype-11: Outsourcing The Influence of Market Maturity on the Development of HealthTech Organizational Forms Building Successful HealthTech Teams for the Next 3-5 Years For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
an hour ago
- Business Upturn
Natrion awarded $250,000 in NSF Energy Storage Engine grants to advance safe and reliable lithium-ion batteries
BINGHAMTON, N.Y., June 09, 2025 (GLOBE NEWSWIRE) — Natrion, a leader in advanced battery technology, has been awarded a $150,000 R&D grant and a $100,000 SuperBoost grant from the National Science Foundation Energy Storage Engine in Upstate New York. The funding will accelerate the commercialization of Natrion's LISIC solid-state electrolyte separator technology, a breakthrough in lithium-ion battery safety, reliability, and thermal stability for electric mobility, grid storage, and aerospace applications. Natrion's proprietary LISIC solid electrolyte separator technology mitigates risks associated with thermal runaway, addressing one of the most significant safety challenges in lithium-ion batteries. By replacing porous separators containing flammable liquid electrolytes with its advanced non-porous solid-state separator, Natrion enhances battery safety while maintaining high energy density and stability. This transformative solution also integrates seamlessly with existing manufacturing processes, enabling cost-effective scaling. 'The energy storage industry has long sought safer, high-performance alternatives to conventional lithium-ion technology,' said Alex Kosyakov, CEO of Natrion. 'This support from the NSF Energy Storage Engine is a game-changer for us, allowing us to accelerate the commercialization of our LISIC separator technology and bring it to real-world applications. By leveraging the world-class testing facilities at Rochester Institute of Technology, we are optimizing our platform for electric vehicles, aerospace, and beyond.' The R&D grant will focus on enhancing the LISIC platform's performance, cost-effectiveness, and manufacturability, while the SuperBoost grant will support rapid prototyping, quality control, and production automation efforts. Natrion will collaborate with RIT's Battery Development Center, using its state-of-the-art facilities to validate the technology for cylindrical batteries, widely used in electric mobility, electronics, and grid applications. The SuperBoost program, a core initiative of the NSF Energy Storage Engine, is designed to accelerate commercialization timelines — reducing the traditional five-plus-year development cycle to under two years. The program provides direct funding, strategic partnerships, and infrastructure access, helping early-stage companies bridge the gap between technological innovation and market deployment. Fernando Gómez-Baquero, director of the Translation Pillar at the Energy Storage Engine, highlighted the critical role of Natrion's advancements in battery safety: 'Battery safety is paramount as the world moves toward widespread electrification. Natrion's LISIC technology directly addresses one of the industry's greatest challenges — thermal runaway — while enhancing energy density and manufacturability. SuperBoost isn't just about funding; it's about ensuring that companies like Natrion have the right ecosystem support to scale and succeed.' The NSF Energy Storage Engine is at the forefront of creating a national energy storage ecosystem, leveraging its extensive network of testbeds, infrastructure, and research collaborations to help startups accelerate their path to market. Meera Sampath, CEO of the NSF Energy Storage Engine, emphasized the Engine's role in strengthening the U.S. energy supply chain: 'The Engine is committed to fostering technology translation and commercialization through strategic investments like SuperBoost. By leveraging upstate New York's unparalleled network of testbeds, manufacturing capabilities, and industry partnerships, we are strengthening the energy storage supply chain and positioning the region as a leader in battery innovation. Natrion's advancements exemplify our mission to accelerate solutions that will drive U.S. energy independence and economic growth.' Through the support of the NSF Energy Storage Engine, Natrion is well-positioned to accelerate its technology toward commercial deployment. By leveraging the Engine's regional resources — including collaborations with RIT's Battery Development Center and other key partners — the company is advancing its battery technology toward full-scale production. This initiative aligns with the Engine's broader mission to transform upstate New York into America's Battery Capital, fostering economic growth, national energy security, and technological leadership in next-generation energy storage. About Natrion Natrion develops advanced battery technologies to deliver safe, scalable, and high-performance energy storage solutions for EVs, aviation, grid storage, and beyond. With a focus on innovation, cost-efficiency, and seamless integration into existing manufacturing, Natrion is redefining the future of energy storage. For more information, visit Contact: Alex Kosyakov CEO & Co-Founder [email protected] m About the NSF Energy Storage Engine in Upstate New York The NSF Energy Storage Engine in Upstate New York, led by Binghamton University, is a National Science Foundation-funded, place-based innovation program. The coalition of 40+ academic, industry, nonprofit, state, and community organizations includes Cornell University, Rochester Institute of Technology, Syracuse University, Launch-NY and NY-BEST as core partners. The Engine advances next-gen battery technology development and manufacturing to drive economic growth and bolster national security. Its vision is to transform upstate New York into America's Battery Capital. For more information on the Upstate New York Energy Storage Engine, visit . Contact: Fernando Gómez-Baquero, Ph.D. Translation Pillar DirectorNSF Energy Storage Engine in Upstate New York [email protected]
